Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the psychosis market grown over the years?

The market size for psychosis has been experiencing robust expansion in the past couple of years. The market is projected to escalate from $9.88 billion in 2024 to $10.49 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. This surge in the historical phase is linked to the escalating instances of mental health disorders, an increasing demand for mental health treatment solutions, a broad acceptance of typical antipsychotics, an expanding application of cognitive behavioral therapy, along with the pervasiveness of stressful global and economic circumstances.

What Is the forecasted market size and growth rate for the psychosis market?

Over the coming years, the psychosis market is projected to experience significant expansion. It is forecasted to reach a value of $13.13 billion by 2029, with a compounded annual growth rate of 5.8%. Factors contributing to this anticipated growth within the projected period include a rise in stress prevalence and correlated risks, increasing mental health issues due to changes in lifestyle, enhanced government initiatives, growing inclination for mindfulness-based treatments and programs, and increased funding in mental health studies and groundbreaking therapies. Key trends expected during the forecast period are the development of new drug treatments, progression in diagnostic technologies, the emergence of innovative injectable medicines, utilization of biomarkers, and the need for individualized medications.

Get your psychosis market report here!

https://www.thebusinessresearchcompany.com/report/psychosis-global-market-report

What are the major factors driving growth in the psychosis market?

The escalating instances of mental health disorders are poised to boost the expansion of the psychosis market. Mental health disorders are conditions that significantly affect a person’s emotional state, thought processes, conduct, and overall mental health. The factors contributing to this escalation of mental health issues include increasing stress levels, shifts in lifestyle, social seclusion, financial pressures, and hereditary factors. Psychosis treatments aid patients by offering early detection, medical intervention, and specialized therapeutic methods, which consequently results in a surge in the use of antipsychotic drugs and therapy alternatives. For example, as projected by the National Alliance On Mental Illness, a U.S. based organization, psychosis spectrum and mood disorders result in approximately 600,000 hospitalizations per year among individuals aged 18-44 in the U.S. Hence, the escalating instances of mental health disorders are propelling the expansion of the psychosis market.

What key areas define the segmentation of the global psychosis Market?

The psychosis market covered in this report is segmented –

1) By Product: Tablet, Capsule, Injection

2) By Disease Type: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Disease Types

3) By Distribution Channel: Online, Offline

4) By End-User: Hospitals, Healthcare Clinics, Speciality Clinics, Other End-Users

Subsegments:

1) By Tablet: Antipsychotic Tablets, Mood Stabilizer Tablets

2) By Capsule: Antipsychotic Capsules, Antidepressant Capsules

3) By Injection: Long-acting Injectable Antipsychotics, Short-acting Injectable Antipsychotics

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21266&type=smp

What are the top market players propelling the growth of the psychosis industry?

Major companies operating in the psychosis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Biogen Idec, Dr. Reddy’s Laboratories Ltd., Lundbeck A/S, Gedeon Richter, Alkermes, Supernus Pharmaceuticals, Acadia Pharmaceuticals, Neuron Pharmaceuticals, Mapi Pharma, Astellas Pharma Inc., Newron Pharmaceuticals S.p.A., Anavex Life Sciences, BioXcel Therapeutics

What key trends are currently impacting the psychosis market’s development?

Leading firms in the psychosis market are concentrating on developing progressive virtual reality (VR) psychological therapies to enhance the results of treatments with interactive and personalized mental health strategies. The concept of VR psychological therapy involves immersing patients within a controlled, computer-generated setting to help alleviate distress, improve cognitive abilities, and enhance social skills through pre-designed interventions, making it a safe and effective method for symptom management. For example, OxfordVR, a US-based digital therapeutics firm, introduced a product named gameChangeVR in April 2022. This product guides patients through cognitive behavioral therapy (CBT) in comprehensive virtual environments. This VR therapy, which is automated and delivered over six weekly sessions, has proven its value, particularly for those dealing with severe psychological issues by improving their paranoia symptoms and overall life quality. This innovative technology could potentially revolutionize the accessibility of effective mental health treatments, overcoming the scarcity of medical professionals and presenting a scalable solution to aid millions of patients suffering from severe mental disorders.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21266

What regions are dominating the psychosis market growth?

North America was the largest region in the psychosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Insulin Biosimilars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

Insulin Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Non-injectable Insulin Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: